Patents by Inventor Stuart Hayden
Stuart Hayden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10407400Abstract: The present disclosure provides edible compositions comprising a flavor-grade sweet taste modulator or a combination of flavor-grade sweet taste modulators or a flavor-grade bitter taste blocker or a combination of flavor-grade bitter taste blockers of the present disclosure, food products comprising such edible compositions and methods of preparing such food products. The present disclosure also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste or blocking a bitter taste in a food product.Type: GrantFiled: January 13, 2016Date of Patent: September 10, 2019Assignee: Chromocell CorporationInventors: Deshou Jiang, Hao Zhou, Stuart Hayden
-
Publication number: 20180002306Abstract: The present disclosure provides edible compositions comprising a flavor-grade sweet taste modulator or a combination of flavor-grade sweet taste modulators or a flavor-grade bitter taste blocker or a combination of flavor-grade bitter taste blockers of the present disclosure, food products comprising such edible compositions and methods of preparing such food products. The present disclosure also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste or blocking a bitter taste in a food product.Type: ApplicationFiled: January 13, 2016Publication date: January 4, 2018Inventors: Deshou Jiang, Hao Zhou, Stuart Hayden
-
Publication number: 20160015064Abstract: The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.Type: ApplicationFiled: March 14, 2014Publication date: January 21, 2016Applicant: CHROMOCELL CORPORATIONInventors: Robert Zhiyong Luo, Kevin Joseph Curran, Stuart Hayden, Gengcheng Yang, Deshou Jiang, Vincent Kral
-
Publication number: 20150050410Abstract: The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.Type: ApplicationFiled: March 14, 2014Publication date: February 19, 2015Applicant: CHROMOCELL CORPORATIONInventors: Robert Zhiyong Luo, Kevin Joseph Curran, Stuart Hayden, Gengcheng Yang
-
Patent number: 8501732Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: GrantFiled: July 11, 2012Date of Patent: August 6, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Joseph A. Bilotta, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Stuart Hayden, Nancy-Ellen Haynes, Christine M. Lukacs-Lesburg, Nicholas Marcopulos, Eric Mertz, Lida Qi, Yimin Qian, Sung-Sau So, Jenny Tan, Kshitij C. Thakkar
-
Publication number: 20130018043Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: ApplicationFiled: July 11, 2012Publication date: January 17, 2013Inventors: Joseph A. Bilotta, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Stuart Hayden, Nancy-Ellen Haynes, Christine M. Lukacs-Lesburg, Nicholas Marcopulos, Eric Mertz, Lida Qi, Yimin Qian, Sung-Sau So, Jenny Tan, Kshitij C. Thakkar
-
Patent number: 8211884Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.Type: GrantFiled: July 23, 2009Date of Patent: July 3, 2012Assignee: Madrigal Pharmaceuticals, Inc.Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian
-
Patent number: 8124766Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.Type: GrantFiled: November 18, 2009Date of Patent: February 28, 2012Assignee: Madrigal Pharmaceuticals, Inc.Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian, Weiya Yun
-
Publication number: 20110136792Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: ApplicationFiled: October 20, 2010Publication date: June 9, 2011Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian, Kshitij Chhabilbhai Thakkar
-
Publication number: 20110112147Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: ApplicationFiled: October 5, 2010Publication date: May 12, 2011Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian
-
Patent number: 7741327Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: GrantFiled: March 9, 2009Date of Patent: June 22, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, John A Brinkman, Stuart Hayden, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
-
Publication number: 20100145047Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.Type: ApplicationFiled: November 18, 2009Publication date: June 10, 2010Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian, Weiya Yun
-
Publication number: 20100035864Abstract: Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type 11 diabetes mellitus and metabolic syndrome.Type: ApplicationFiled: July 23, 2009Publication date: February 11, 2010Inventors: David Robert Bolin, Stuart Hayden, Yimin Qian
-
Publication number: 20090264445Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: ApplicationFiled: March 9, 2009Publication date: October 22, 2009Inventors: Steven Joseph Berthel, John A. Brinkman, Stuart Hayden, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
-
Patent number: 7579356Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.Type: GrantFiled: April 10, 2006Date of Patent: August 25, 2009Assignee: Janssen Pharmaceutica NVInventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Niranjan B. Pandey, Mark T. Powell
-
Publication number: 20080300264Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: August 14, 2008Publication date: December 4, 2008Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
-
Patent number: 7427625Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: GrantFiled: February 7, 2007Date of Patent: September 23, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
-
Publication number: 20080108611Abstract: The present invention is directed to thienopyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: January 10, 2007Publication date: May 8, 2008Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
-
Publication number: 20070265264Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.Type: ApplicationFiled: April 10, 2006Publication date: November 15, 2007Inventors: Kathleen Battista, Gilles Bignan, Peter Connolly, Stuart Hayden, Sigmond Johnson, Ronghui Lin, Niranjan Pandey, Mark Powell
-
Publication number: 20070225309Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: February 7, 2007Publication date: September 27, 2007Inventors: Peter Connolly, Stuart Emanuel, Stuart Hayden, Sigmond Johnson, Bharat Lagu, Steven Middleton, Niranjan Pandey, Mark Powell